Abstract

<div>Abstract<p><b>Purpose:</b> Tumor-associated macrophages (TAMs) in malignant tumors have been linked to tumor aggressiveness and represent a new target for cancer immunotherapy. As new TAM-targeted immunotherapies are entering clinical trials, it is important to detect and quantify TAM with noninvasive imaging techniques. The purpose of this study was to determine if ferumoxytol-enhanced MRI can detect TAM in lymphomas and bone sarcomas of pediatric patients and young adults.</p><p><b>Experimental Design:</b> In a <i>first-in-patient</i>, Institutional Review Board–approved prospective clinical trial, 25 pediatric and young adult patients with lymphoma or bone sarcoma underwent ferumoxytol-enhanced MRI. To confirm ferumoxytol enhancement, five pilot patients (two lymphoma and three bone sarcoma) underwent pre- and postcontrast MRI. Subsequently, 20 patients (10 lymphoma and 10 bone sarcoma) underwent ferumoxytol-enhanced MRI 24 to 48 hours after i.v. injection, followed by tumor biopsy/resection and macrophage staining. To determine if ferumoxytol-MRI can differentiate tumors with different TAM content, we compared T2* relaxation times of lymphomas and bone sarcomas. Tumor T2* values of 20 patients were correlated with CD68<sup>+</sup> and CD163<sup>+</sup> TAM quantities on histopathology.</p><p><b>Results:</b> Significant ferumoxytol tumor enhancement was noted on postcontrast scans compared with precontrast scans (<i>P</i> = 0.036). Bone sarcomas and lymphomas demonstrated significantly different MRI enhancement and TAM density (<i>P</i> < 0.05). Within each tumor group, T2* signal enhancement on MR images correlated significantly with the density of CD68<sup>+</sup> and CD163<sup>+</sup> TAM (<i>P</i> < 0.05).</p><p><b>Conclusions:</b> Ferumoxytol-enhanced MRI is immediately clinically applicable and could be used to stratify patients with TAM-rich tumors to immune-targeted therapies and to monitor tumor response to these therapies. <i>Clin Cancer Res; 24(17); 4110–8. ©2018 AACR</i>.</p></div>

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.